Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
HealthAtWork - a measure for increased coping and work participation -An effect analysis of a health- and work environment intervention at the workplace. Part 1:quantitative data collection The main objective of this study is to investigate the effect of the workplace intervention in the new Norwegian national concept HealthAtWork (HelseIArbeid) through a pragmatic cluster-randomized study. The main hypothesis is that this interdisciplinary health and welfare intervention at the workplace reduces sick leave and improves mastering of common health problems more efficiently than a conventional welfare intervention. More specifically, it is hypothesized that the HealthAtWork intervention has a better cost-effectiveness in terms of sick leave, use of health services and coping with common health problems indicated by an increased health-related quality of life.
Description: Sickness absence data from workplace-registers; Difference-in-difference analyses of sickness absence within and between intervention and control group (% of planned workdays).
Measure: Change in overall sickness absence rates (self- and physician-certified) at the workplace (unit level) Time: Time period 24 months prior to randomization compared to the time period 12-24 months after randomizationDescription: Difference-in-difference analyses of health service refunds from National register of control and health service refunds (KUHR database, Helsedirektoratet) and Norwegian Patient Register (NPR, Helsedirektoratet) within and between intervention and control group.
Measure: Change in healthcare utilization Time: Time period 24 months prior to randomization compared to the time period 12-24 months after randomizationDescription: Difference-in-difference analyses of HRQoL within and between intervention and control groups by use of EQ-5D/EQ-VAS.The EuroQol descriptive system EQ-5D-5L describes health along five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Participants rate each dimension along five severity levels from no problems (1) to extreme problems (5).The resulting combination (5 to the power of 5 = 3,125 possible combinations) is attached a utility value based on a national value set on a scale from 1(best health) to a 0(or even lower) for worst health.A Norwegian value set is currently being developed.The EQ-VAS (EuroQol vertical visual analogue scale;0 as worst,100 as best possible score) is an integral part that has to be included when using the EQ-5D questionnaire.It offers important, complementary information on respondents' valuations of their HRQoL that are not necessarily captured by use of the 5 dimensional descriptive part of this instrument.
Measure: Change in health-related quality of life (HRQoL) by EQ-5D-5L utility value, including EQ-VAS score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Cost-effectiveness analysis based on primary outcome 3 and cost-benefit analyses based on primary outcome 1 and 2. Comparing the intervention arms in terms of incremental costs based on direct- and indirect costs related to interventions throughout the intervention period.
Measure: Health-economic analyses Time: Time period 24 months prior to randomization through 24 months after randomizationDescription: Data from the Norwegian national register of sickness absence (NAV sykefraværsregister); Difference-in-difference analyses of individual sickness absence rates within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in physician-certified sickness absence rates (individual level) Time: Time period 24 months prior to randomization compared to the time period 12-24 months after randomizationDescription: Data from the questionnaires; Difference-in-difference analyses of self-certified sickness absence rates within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in self-certified sickness absence rates (individual level) Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Demand-Control-Support-Questionnaire, short Swedish version (Theorell et al 1991), 11 items on demand and control, and 6 items on support, each with scores 1-4, subscales for demand, control and support. Low scores indicate low demand, control and support. Difference-in-difference analyses of psychosocial work environment within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in psychosocial work environment by Demand-Control-Support-Questionnaire score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Nondirective and Directive support Survey (NDSS-16). 16 items scored 1-5. Subscales for directive support (8 items, scale 8-40) and non-directive support (8 items, scale 8-40), the higher the score the more support. Difference-in-difference analyses of social support from colleagues within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in social support from colleagues by NDSS-16 score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Global Job Satisfaction (GJS). Quinn and Shepard, 1974, 5 items scores 1-5 and 1-3, highest number indicate best job satisfaction. Difference-in-difference analyses of job satisfaction within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in job satisfaction by GJS score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Subjective Health Complaints (SHC), Eriksen et al. 1999, 29 items scored with 4 levels from 0 (no complaints) to 3 (serious complaints), total score and subscale for mental complaints and musculoskeletal pain. Difference-in-difference analyses of subjective health complaints within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in subjective health complaints by SHC score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Change in score of the Whitheley index. The Whiteley-7 index (WI-7) includes questions regarding health anxiety covering different dimensions such as self-experienced health concern, frequency and severity of health concerns, influence of media on subjective health concerns and experiencing of health symptoms. Each response is graded on a 1-5 Likert Scale, where "1=not at all" to "5=very much", enabling to calculate a product score of maximum 35, a higher value indicating higher level of health anxiety. The 7th question in the Norwegian version of WI-7 is not validated for use in a general Norwegian population and is therefore not included in the use of total score sum. It can, however, be used for repeated analyses, both within study time and for comparison with data from the Tromsø study 7. Difference-in-difference analyses of health anxiety within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in health anxiety by Whitheley index score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomization; comparison with Tromsø Study 7Description: Satisfaction of life scale (SWLS). Five items where each has response options ranged from 1 (strongly disagree) to 7 (strongly agree), sum score is calculated. The higher the sum score, the higher is the satisfaction of life. Change in sum score of the first 3 items (the last two are sensitive to age). Difference-in-difference analyses of subjective health complaints within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in Satisfaction of life by SWLS score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports